September 15, 2018Open Access

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

Key Points

Key points are not available for this paper at this time.

Abstract

In this integrated analysis of patients with moderate to severe active RA with exposure up to 5.5 years, baricitinib has an acceptable safety profile in the context of demonstrated efficacy. Trial registration numbers: NCT01185353, NCT00902486, NCT01469013, NCT01710358, NCT01721044, NCT01721057, NCT01711359, and NCT01885078 at clinicaltrials.gov.

Bookmark

View Full Paper

Cite This Study

Smolen et al. (Sat,) studied this question.

synapsesocial.com/papers/69dfedae60d9fa30ca7a10d6 https://doi.org/https://doi.org/10.3899/jrheum.171361

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB0280502010 · 463 citations
2A potential bias in safety evaluation during open‐label extensions of randomized clinical trials2004 · 20 citations
3Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report2002 · 14,070 citations
4Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.2007 · 190 citations
5Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study2016 · 497 citations

Bookmark

View Full Paper